Surge in Antidepressant Sales Across India

In the wake of the Covid-19 pandemic, India has witnessed a significant surge in the sales of antidepressants and mood elevators. The market, valued at Rs 1,540 crore in 2020, soared to Rs 2,536 crore by November 2024, marking a 64% increase. This growth is attributed to the shift towards virtual consultations and a greater awareness of mental health issues.

Leading Medications in the Market

Among the top-selling medications is a combination of Escitalopram and Clonazepam, with a 59.35% increase in sales since 2020. Escitalopram is known for treating depression and anxiety by boosting serotonin levels, while Clonazepam is prescribed for anxiety, panic attacks, and seizures. Sertraline, another widely used antidepressant, saw a 48.2% growth, used for treating depression, OCD, and PTSD.

Experts Weigh In

Dr. Vishal Sawant and Dr. Harish Shetty, prominent psychiatrists, highlighted the efficacy of these medications and the growing acceptance of mental health treatment in India. Dr. Neena Sawant noted the positive trend of more people seeking help, with general physicians now prescribing antidepressants in moderation.

Government and Helpline Support

Government-supported mental health helplines like Tele Manas and iCall have played a crucial role in providing access to counseling, with iCall receiving thousands of calls monthly. This reflects a significant shift in societal attitudes towards mental health care in India.